Associations between declining testosterone concentrations and cognitive performance in community-dwelling older Australian women: a prospective cohort study.

IF 3.2 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Climacteric Pub Date : 2025-08-14 DOI:10.1080/13697137.2025.2539854

Farhana Sultana, Rakibul M Islam, Susan R Davis

{"title":"Associations between declining testosterone concentrations and cognitive performance in community-dwelling older Australian women: a prospective cohort study.","authors":"Farhana Sultana, Rakibul M Islam, Susan R Davis","doi":"10.1080/13697137.2025.2539854","DOIUrl":null,"url":null,"abstract":"Objective: Testosterone may have a role in brain health. Whether older women who exhibit a decline in blood testosterone are at an increased risk of cognitive decline is uncertain.Method: A subset of Australian female participants in the Aspirin in Reducing Events in the Elderly (ASPREE) trial had testosterone concentrations measured by liquid chromatography-tandem mass spectrometry and underwent a comprehensive cognitive test battery at baseline and study year 3. Cognitive decline was defined as a lower test score at year 3 compared with baseline. The mean change (baseline to year 3) of testosterone concentration was examined by paired-sample t-test. Stable or increased (reference) versus a decline in testosterone concentration was used to investigate the association with cognitive decline using logistic regression.Results: A total of 395 women (median [interquartile range] age 78.1 [73.7-82.3] years) provided data for analysis. In total, 154 women (39%) had a decline in blood testosterone which was not associated with a decline in any cognitive measure (Modified Mini-Mental State Examination: odds ratio [OR] = 0.96, 95% confidence interval [CI] 0.63 to 1.49, p = 0.86; Hopkins Verbal Learning Test - Revised: Immediate Recall, OR = 0.71, 95% CI 0.44 to 1.13, p = 0.151 and Delayed Recall, OR = 1.42, 95% CI 0.89 to 2.26, p = 0.14; Controlled Oral Word Association Test: OR = 0.79, 95% CI 0.49 to 1.25, p = 0.31; and Symbol Digit Modalities Test: OR = 0.83, 95% CI 0.53 to 1.29, p = 0.40). Limiting the analysis to 237 women aged 70-79 years (74.5 [interquartile range 72.2-77.1] years), no association was observed between a decline in blood testosterone and any cognitive outcome.Conclusion: : A decline in blood testosterone concentrations over 3 years was not associated with a decline in cognitive function in community-dwelling Australian women aged 70 years and older.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-7"},"PeriodicalIF":3.2000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2025.2539854","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Testosterone may have a role in brain health. Whether older women who exhibit a decline in blood testosterone are at an increased risk of cognitive decline is uncertain.

Method: A subset of Australian female participants in the Aspirin in Reducing Events in the Elderly (ASPREE) trial had testosterone concentrations measured by liquid chromatography-tandem mass spectrometry and underwent a comprehensive cognitive test battery at baseline and study year 3. Cognitive decline was defined as a lower test score at year 3 compared with baseline. The mean change (baseline to year 3) of testosterone concentration was examined by paired-sample t-test. Stable or increased (reference) versus a decline in testosterone concentration was used to investigate the association with cognitive decline using logistic regression.

Results: A total of 395 women (median [interquartile range] age 78.1 [73.7-82.3] years) provided data for analysis. In total, 154 women (39%) had a decline in blood testosterone which was not associated with a decline in any cognitive measure (Modified Mini-Mental State Examination: odds ratio [OR] = 0.96, 95% confidence interval [CI] 0.63 to 1.49, p = 0.86; Hopkins Verbal Learning Test - Revised: Immediate Recall, OR = 0.71, 95% CI 0.44 to 1.13, p = 0.151 and Delayed Recall, OR = 1.42, 95% CI 0.89 to 2.26, p = 0.14; Controlled Oral Word Association Test: OR = 0.79, 95% CI 0.49 to 1.25, p = 0.31; and Symbol Digit Modalities Test: OR = 0.83, 95% CI 0.53 to 1.29, p = 0.40). Limiting the analysis to 237 women aged 70-79 years (74.5 [interquartile range 72.2-77.1] years), no association was observed between a decline in blood testosterone and any cognitive outcome.

Conclusion: : A decline in blood testosterone concentrations over 3 years was not associated with a decline in cognitive function in community-dwelling Australian women aged 70 years and older.

查看原文本刊更多论文

澳大利亚社区老年妇女睾酮浓度下降与认知能力之间的关系：一项前瞻性队列研究。

目的：睾酮可能在大脑健康中发挥作用。血液中睾酮水平下降的老年女性是否存在认知能力下降的风险增加尚不确定。方法：在阿司匹林减少老年人事件（ASPREE）试验中，一部分澳大利亚女性参与者通过液相色谱-串联质谱法测量睾酮浓度，并在基线和研究第3年进行全面的认知测试。认知能力下降被定义为与基线相比，第三年的测试成绩较低。睾酮浓度的平均变化（基线至第3年）采用配对样本t检验。使用逻辑回归来研究睾酮浓度稳定或增加（参考）与下降与认知能力下降的关系。结果：共有395名女性（中位数[四分位数间距]78.1[73.7-82.3]岁）提供数据进行分析。总共有154名女性（39%）的血睾酮水平下降，但与任何认知功能的下降无关(修正迷你精神状态检查：优势比[OR] = 0.96, 95%可信区间[CI] 0.63 ~ 1.49, p = 0.86；霍普金斯语言学习测试-修订：即时回忆，OR = 0.71, 95% CI 0.44至1.13,p = 0.151；延迟回忆，OR = 1.42, 95% CI 0.89至2.26,p = 0.14；对照口语单词联想测试：OR = 0.79, 95% CI 0.49 ~ 1.25, p = 0.31；符号数字模态检验：OR = 0.83, 95% CI 0.53 ~ 1.29, p = 0.40)。将分析限制在237名年龄在70-79岁（74.5[四分位数间距72.2-77.1]岁）的女性中，未观察到血睾酮下降与任何认知结果之间的关联。结论：在澳大利亚社区居住的70岁及以上妇女中，血液睾酮浓度3年以上的下降与认知功能的下降无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Climacteric 医学-妇产科学

CiteScore

1.70

自引率

7.10%

发文量

审稿时长

1 months

期刊介绍： Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.